CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized, Double-blind, Parallel-group, Multicenter, Phase III Prospective Non-inferiority Clinical Trial to Assess Efficacy and Safety of Nasacort® Nasal Spray (Triamcinolone, 55µg) in Comparison With Flixonase® Nasal Spray (Fluticasone, 50 µg) in Adults Suffering From PAR (Perennial Allergic Rhinitis) Administered Once a Day for 28 Days

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03317015
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:41.733047+00:00
Published At: 2022-04-25T00:00:00+00:00
Record Updated At: 2022-04-25
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Rhinitis Allergic"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-04-25"
protocolSection.identificationModule.nctId: "NCT03317015"
protocolSection.identificationModule.officialTitle: "A Randomized, Double-blind, Parallel-group, Multicenter, Phase III Prospective Non-inferiority Clinical Trial to Assess Efficacy and Safety of Nasacort\u00ae Nasal Spray (Triamcinolone, 55\u00b5g) in Comparison With Flixonase\u00ae Nasal Spray (Fluticasone, 50 \u00b5g) in Adults Suffering From PAR (Perennial Allergic Rhinitis) Administered Once a Day for 28 Days"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.